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Abstract 
Background: Ae. aegypti mosquitoes stably transfected with the 
intracellular bacterium Wolbachia pipientis (wMel strain) have been 
deployed for biocontrol of dengue and related arboviral diseases in 
multiple countries. Field releases in northern Australia have previously 
demonstrated near elimination of local dengue transmission from 
Wolbachia-treated communities, and pilot studies in Indonesia have 
demonstrated the feasibility and acceptability of the method. We 
conducted a quasi-experimental trial to evaluate the impact of scaled 
Wolbachia releases on dengue incidence in an endemic setting in 
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Indonesia. 
Methods: In Yogyakarta City, Indonesia, following extensive 
community engagement, wMel Wolbachia-carrying mosquitoes were 
released every two weeks for 13–15 rounds over seven months in 
2016–17, in a contiguous 5 km2 area (population 65,000). A 3 km2 area 
(population 34,000) on the opposite side of the city was selected a 
priori as an untreated control area. Passive surveillance data on 
notified hospitalised dengue patients was used to evaluate the 
epidemiological impact of Wolbachia deployments, using controlled 
interrupted time-series analysis. 
Results: Rapid and sustained introgression of wMel Wolbachia into 
local Ae. aegypti populations was achieved. Thirty-four dengue cases 
were notified from the intervention area and 53 from the control area 
(incidence 26 vs 79 per 100,000 person-years) during 24 months 
following Wolbachia deployment. This corresponded in the regression 
model to a 73% reduction in dengue incidence (95% confidence 
interval 49%,86%) associated with the Wolbachia intervention. 
Exploratory analysis including 6 months additional post-intervention 
observations showed a small strengthening of this effect (30 vs 115 
per 100,000 person-years; 76% reduction in incidence, 95%CI 
60%,86%). 
Conclusions: We demonstrate a significant reduction in dengue 
incidence following successful introgression of Wolbachia into local Ae. 
aegypti populations in an endemic setting in Indonesia. These findings 
are consistent with previous field trials in northern Australia, and 
support the effectiveness of this novel approach for dengue control.
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DHF: dengue haemorrhagic fever
DHO: District Health Office
ICD-10: International Classification of Diseases, 10th revision
IRR: incidence rate ratio
ITS: interrupted time series
MRC: mosquito release container
NS1: non-structural protein 1
QA: quality assurance
RDT: rapid diagnostic test
RT-PCR: reverse transcription polymerase chain reaction
WMP : World Mosquito Program
Background
Aedes aegypti mosquitoes are the primary vectors of dengue, 
Zika and chikungunya viruses. Of these, dengue is the most 
common arboviral infection of humans. Indonesia has among 
the highest dengue case burden, with an estimated 10 million 
clinical cases and 3000 deaths each year1. The annual per 
capita incidence is estimated at 36–44 symptomatic cases 
per 1000 population1,2 with a resultant cost in excess of 
USD $2 billion per annum3. Yogyakarta is typical of many cities 
in Indonesia; dengue is endemic with a seasonal peak between 
November and May. The high force of infection in Yogyakarta 
is evidenced by the hospitalised dengue case burden and high 
seroprevalence of dengue virus (DENV) neutralising antibodies 
(68%) in children 1–10 years4.
The World Mosquito Program (WMP) is an international research 
collaboration deploying Wolbachia-infected Ae. aegypti mos-
quitoes for the biocontrol of dengue and other Ae. aegypti-borne 
viral infections. Wolbachia is an intracellular endosymbiotic 
bacterium present naturally in many insect species, but not 
present in Ae. aegypti until methods enabling stable transinfec-
tion emerged5. Wolbachia is maintained in Ae. aegypti through 
maternal inheritance, and confers a reproductive advantage via 
cytoplasmic incompatibility which facilitates its introgression 
into mosquito populations following open field release. A sec-
ond feature of wMel Wolbachia in Ae. aegypti is that it con-
fers resistance to infection with all four DENV serotypes6–9 plus 
other medically important arboviruses like chikungunya, Zika 
and Yellow Fever10–14. Mathematical modelling predicts that the 
wMel strain of Wolbachia should eliminate DENV transmission 
in most endemic country epidemiological circumstances7,15,16.
The first open releases of wMel Wolbachia-carrying Ae. aegypti 
were undertaken in northern Australia, in small isolated com-
munities in 2011 and then into contiguous urban areas from 
2013, resulting in the near elimination of local dengue trans-
mission in northern Australia17,18. In 2014–15, WMP conducted 
small-scale field trials in four small peri-urban communities 
(0.18–0.61 km2; populations of 1157–2681) in Sleman and 
Bantul districts in Yogyakarta Province, Indonesia19. These 
proof-of-concept trials demonstrated successful introgression 
and long-term persistence of Wolbachia in local Ae. aegypti 
populations.
On the basis of these promising results, wMel Wolbachia- 
carrying mosquitoes were deployed in the city of Yogyakarta 
in 2016–2017 with the dual aims of optimising methods 
for deployment at scale and demonstrating a reduction in 
arboviral disease incidence. Two consecutive prospective 
studies were conducted to evaluate the public health impact of 
Wolbachia releases in non-overlapping areas of Yogyakarta city 
(Figure 1). The first, reported here, was a quasi-experimental 
study in which interrupted time series analysis20 of routine 
dengue surveillance data was used to evaluate the epidemio-
logical impact of Wolbachia deployments in one contiguous 
area on the urban fringe, in comparison to a pre-speci-
fied untreated control area. The second study was a cluster 
randomised controlled trial (Applying Wolbachia to Eliminate 
Dengue (AWED); ClinicalTrials.gov #NCT03055585)21. Par-
ticipant enrolment in the AWED trial is ongoing until late 2020, 
and no results are reported here.
The entomological and epidemiological results of the quasi- 
experimental study, at the a priori defined two year time point 
after Wolbachia deployment and with six months additional 
observation time, are reported here. They demonstrate a sig-
nificant and sustained reduction in notified dengue haemorrhagic 
fever (DHF) case incidence in Wolbachia-treated communities.
Methods
Study setting
Yogyakarta City in south-central Java, Indonesia, has a population 
of 422,732 in an area of 32 km2, with 14 administrative districts 
comprising 45 kelurahans (urban villages). Seven kelurahans 
(total population 64,599; area 4.9 km2) on the north-western 
perimeter of the city were selected as the site for scaled deploy-
ment of Wolbachia-carrying mosquitoes (Figure 1), on the 
basis of logistical and operational feasibility. Three kelurahans 
(population 33,535; 3.1 km2) on the south-eastern perimeter 
were selected a priori as an untreated control area, on the basis 
of comparable socio-demographic characteristics (Table 1) and 
historical dengue incidence.
Community engagement
A Public Acceptance Model17 was applied in engaging with the 
local community prior to Wolbachia deployments, and through-
out the release and monitoring periods. Key elements of this 
approach included: meetings with key stakeholders and com-
munity leaders; meetings and ongoing regular communication 
with existing community reference groups at the village, city 
and provincial level; a communications campaign through social 
media, traditional media, mobile billboards, and community 
events; a household-based survey to evaluate awareness and 
acceptance prior to releases; and a ‘stakeholder enquiry system’ 
to receive and respond to any issues arising from stakeholders or 
community members.
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Table 1. Characteristics of intervention and control areas.
Area Total size (km2) Total populationa % completed high 
schoolb
% <15 years 
of agea
Intervention 
(7 kelurahans)
4.90 64 599 50% 22%
Control 
(3 kelurahans)
3.07 33 535 49% 23%
Source: aStatistics Indonesia (BPS) Yogyakarta City, 2017; bYogyakarta Province Population Bureau, 2017.
Figure 1. Map of intervention and control areas in the Yogyakarta quasi-experimental study (QES). The study area for the ‘Applying 
Wolbachia to Eliminate Dengue (AWED)’ cluster randomised controlled trial (CRCT), ongoing until late 2020, is also indicated.
A household survey of baseline community acceptance of 
WMP’s Wolbachia method was undertaken in November 2015 
prior to intensive community engagement, followed by a second 
survey in June 2016 to evaluate acceptance prior to commenc-
ing releases. Two-stage cluster random sampling was used to 
select respondent households from across Yogyakarta City: n=587 
in the 2015 survey (of which n=96 were from the seven urban 
villages in the quasi-experimental intervention area) and n=862 
in the 2016 survey (n=180 from the intervention area). The 
sample size in the 2016 pre-release survey was sufficient to 
estimate community acceptance in the quasi-experimental 
intervention area with a margin of error of 10%, under conservative 
assumptions of a true community acceptance rate of 50% and a 
design effect of 2 due to the clustered sampling. Administra-
tive wards were the primary sampling unit, and 12 households 
were randomly selected per ward using a list of households 
provided by the ward head as the sampling frame. The survey 
respondent was the head of household or another adult family 
member; there were no other inclusion or exclusion criteria. 
Respondents were asked about their level support for Wolbachia 
Page 5 of 16
Gates Open Research 2020, 4:50 Last updated: 04 AUG 2020
Figure 2. Insecticide susceptibility of the wMel Ae. aegypti colony and wild-type Ae. aegypti collected from the quasi-experimental 
study intervention area. Bars show mean (st. dev.) % mortality across four replicate tests, each with 20 – 28 mosquitoes tested against each 
insecticide.
releases as a method for controlling dengue in their commu-
nity. The survey participation rate was > 95% in each survey. 
During the 2015 baseline survey 67% of respondents from the 
quasi-experimental intervention area were supportive of the 
release of Wolbachia-infected Ae. aegypti as a new technology 
for controlling dengue, 14% were not supportive, and 20% were 
neutral or did not know. In the 2016 pre-release survey, accept-
ance in the intervention area had increased to 79%; 9% were not 
supportive and 11% were neutral or did not know.
The stakeholder enquiry system was managed by a dedicated 
staff member and enquiries could be logged by phone call, SMS 
text, WhatsApp, email or direct communication with WMP field 
staff. In total we had 216 enquiries during the release phase, relat-
ing to: details of release activities (location, timing, methods) 
(35%), requests for face-to-face meetings with community lead-
ers (25%), expressions of support for the Wolbachia technology 
(18%), reports of dengue cases in the release area (7%), reports 
from householders on the condition of mosquito release containers 
(MRCs) (6%), and refusal to host an MRC (6%).
Mosquito rearing and egg production
An existing colony of local Ae. aegypti containing the wMel 
Wolbachia strain, created in 2013 for pilot releases in Bantul 
District of Yogyakarta Province19, was used as the founder 
colony for the releases described here. It was backcrossed for 
three generations with wild-type males collected from the study 
intervention area. Four cages with 150 wMel-carrying female 
Ae. aegypti and 150 wild-type males were maintained for two 
gonotrophic cycles, and blood-fed by human volunteers. One 
hundred larvae were randomly selected from each cage and 
screened for Wolbachia, and only cages with 100% Wolbachia 
prevalence were maintained for the second backcrossing. An 
open colony was maintained by adding 10% of wild-type Aegypti 
after the second backcrossing. Insecticide resistance testing was 
conducted as described in 22, except that test specimens were 
adult females derived from egg, rather than larval, collections. This 
demonstrated equivalent insecticide resistance profiles between 
the colony and wild material (Figure 2).
Mosquitoes were blood-fed by human volunteers once a week 
for two gonotrophic cycles, as per previous protocols17. All vol-
unteer blood-feeders were afebrile and free of clinical signs or 
symptoms of any arbovirus infection both at the time of blood-
feeding and for three days thereafter. Four days after blood feed-
ing, mosquito eggs were collected by placing oviposition strips 
in each cage for 3 days. Eggs were dried slowly and stored 
in sealed containers until releases.
Quality assurance of mosquito release material
For quality assurance (QA) of the mosquito colony, a sample of 
~1% of eggs from the parent generation of the release material 
was screened for Wolbachia by qualitative PCR Taqman assay on 
a Roche LightCycler 480. The pre-specified minimum acceptable 
Wolbachia prevalence was 97%. In each gonotrophic cycle, nine 
blood-fed female mosquitoes per human volunteer were tested 
for infection with DENV-1–4, chikungunya and Zika virus by 
qRT-PCR as previously described23.
For QA of the release material, eggs from 10 oviposition 
strips were hatched each release week, with a minimum 
threshold hatch rate of 80%. Each release week, 10% of all 
release containers were selected randomly for QA, to estimate 
numbers of mosquitoes released. Eggs from these QA contain-
ers were manually counted under a microscope prior to field 
deployment. Release success was evaluated in the same QA 
containers at the time of servicing two weeks later (see below). 
A container was classified as ‘failed’ if: 1) it was lost; 2) it was 
dry; 3) pupae skin n<25; 4) dead adult mosquitoes >10; 5) wing 
carcass >20; or 6) remaining larvae and pupae >30.
Page 6 of 16
Gates Open Research 2020, 4:50 Last updated: 04 AUG 2020
Table 2. Summary of Wolbachia deployments in seven urban villages.
Kelurahan 
(urban village)
Total area 
(km2)
Release start and end 
date
# release 
rounds
Mean release 
points per round 
(min, max)
Mean estimated 
mosquitoes 
released per 
round (st dev)a
Kricak 0.84 15 Aug 2016 - 13 Feb 2017 15 315 (280, 362) 23 756 (5337)
Pakuncen 0.64 22 Aug 2016 - 6 Mar 2017 14 265 (193, 357) 20 766 (9003)
Patangpuluhan 0.45 24 Aug 2016 - 8 Mar 2017 14 189 (169, 233) 14 401 (4440)
Tegalrejo 0.82 7 Sept 2016 - 8 Mar 2017 13 260 (228, 312) 18 786 (3852)
Bener 0.59 5 Sept 2016 - 6 Mar 2017 13 126 (123, 133) 9005 (1687)
Karangwaru 0.77 15 Sept 2016 - 15 Mar 2017 13 269 (238, 314) 21 564 (4426)
Wirobrajan 0.79 18 Sept 2016 - 13 Mar 2017 13 260 (232, 320) 19 691 (3949)
a The number of mosquitoes released each round in each kelurahan was estimated from the mean number of eggs in the 
mosquito release containers (MRCs) randomly selected for quality assurance (QA), multiplied by the number of successful 
release containers in that kelurahan. Shown here is the mean number (and standard deviation) of mosquitoes released per 
release round, in each kelurahan.
Deployment
Wolbachia-carrying mosquitoes were released as eggs using 
mosquito release containers (MRCs). These were 2-litre plas-
tic buckets each containing one oviposition strip with 100–150 
eggs, Tetra Pleco Wafers fish food (Tetra GmbH, Germany), and 
1 litre of water. MRCs were covered and placed outside houses, 
protected from direct sun and rain. Holes drilled near the top of 
the bucket walls allowed adult mosquitoes to escape. Releases 
occurred between August 2016 and March 2017, with 13–15 
rounds of releases in each kelurahan. Releases stopped in each 
kelurahan when the prevalence of Wolbachia in field-caught 
mosquitoes was >60% for three consecutive weeks releases 
(Table 2). MRCs were reset every two weeks. An MRC was 
placed in 1–2 randomly selected locations within each 50×50 m 
grid square across the intervention area. Permission was obtained 
from property owners to place MRCs on private property. 
Monitoring
Prevalence of Wolbachia in the local Ae. aegypti population was 
monitored by weekly collection of adult mosquitoes via a net-
work of 89 BG Sentinel traps (Biogents, Germany). The median 
(range) trap density was 15.7 (13.0–20.0) BG/km2 in the inter-
vention area and 3.6 (2.0–4.0) BG/km2 in the non-release area. 
Mosquitoes were demobilised at -20°C for ≥1 hour, then iden-
tified by morphological features. The number of mosquitoes 
caught in each BG trap was recorded by species, sex, and in 
total. Ae. aegypti were stored at -20°C in 80% ethanol until 
Wolbachia screening.
Diagnostics
Field-caught Ae. aegypti were screened for wMel Wolbachia 
by qualitative PCR Taqman assay on a Roche LightCycler 480. 
The qPCR conditions consisted of a denaturation step at 95°C 
for 5 minutes followed by 45 cycles of PCR (denaturation at 
95 °C for 10 seconds, annealing at 60 °C for 15 seconds, and 
extension at 72 °C for 1 second with the single acquisition) 
followed by a cooling down step at 40°C for 10 seconds. 
Specific primers targeting the gene encoding Ae aegypti Rps17 
and wMel WD0513 were used as previously described24, but 
with replacement of the Cy5-BHQ3 fluorophore-quencher 
pair in the wMel probe with the fluorophore-quencher 
LC640-IowaBlack (Integrated DNA technologies)25. Testing was 
weekly when Wolbachia prevalence was <80%; two-weekly when 
≥80% and four-weekly when ≥90%.
Epidemiological data
Data on hospitalized dengue haemorrhagic fever (DHF) cases 
(ICD-10 code A91; International Classification of Diseases 10th 
revision) were obtained from the Yogyakarta District Health 
Office (DHO), for January 2006–September 2019. Data on 
hospitalised dengue fever (DF) cases (ICD-10 code A90) 
were also obtained for January 2017–September 2019, as DF 
notification only began in 2017. Data were monthly case counts 
by kelurahan of residence. Population data were obtained from 
the Indonesian Bureau of Statistics. Anonymised results of 
dengue rapid diagnostic tests (RDTs) (SD Bioline Dengue 
Duo, Abbott, USA) performed in 18 primary health care 
clinics across Yogyakarta City from March 2016–September 
2019 were obtained directly from the clinics. RDT results were 
extracted for participants resident in the quasi-experimental 
study intervention or control area, based on the kelurahan of 
residence where available, otherwise the kelurahan of clinic 
location.
Statistical analysis
The crude dengue incidence rate ratio in the pre-intervention 
and post-intervention periods was calculated as the aggregate 
number of DHF cases divided by the aggregate person-months, 
in the intervention area versus the control area. Crude dengue 
incidence was similarly calculated using an endpoint that 
included both DF and DHF case notifications, but only in the 
post-intervention period due to the lack of DF reporting prior to 
January 2017. Spearman’s rank correlation test was used to evaluate 
the correlation in monthly notified dengue incidence between 
the intervention and control areas, in the pre-intervention period. 
The Wolbachia intervention effect was estimated using controlled 
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interrupted time series analysis17,18,20. Negative binomial regres-
sion was used to model monthly DHF case counts in the 
aggregate intervention and control areas, with an offset for 
population size. The primary analysis, defined a priori, included 
data from January 2006 until March 2019, two years post-
release. A secondary analysis included an additional six months 
of data to September 2019. Annual population estimates were 
used for 2006–2013 and 2015–2017; 2013 population estimates 
were used for 2014 and 2017 estimates were used for 2018 and 
2019, due to unavailability of data for those years. Seasonal 
variability in dengue incidence was controlled using 6-monthly 
flexible cubic splines. A binary ‘group’ variable indicated 
the study arm (intervention or control). A binary ‘treatment’ 
variable distinguished the pre-intervention period (up to the end 
of Wolbachia deployments in the last release area) and the post-
intervention period, and the intervention effect was estimated 
from the interaction between the ‘group’ and ‘treatment’ vari-
ables. This allows explicitly for a level change in the outcome 
(dengue case incidence) in both intervention and control arms 
in the post-intervention period, for example in a scenario where 
other secular effects coincident with the Wolbachia deploy-
ments may have influenced dengue incidence independently of 
Wolbachia. The unavailability of DF data prior to January 2017 
precluded an ITS analysis with a combined DF/DHF endpoint. 
Robust standard errors were used for all models. Fisher’s exact 
test was used to compare the proportion of patients with an NS1-
positive RDT result between intervention and control areas, in 
the pre-intervention period and post-Wolbachia deploymnets. 
Analyses were performed using Stata® statistical software 
package version 14.2 (StataCorp, College Station, TX). 
Power calculation
Power was estimated using 1000 simulated datasets drawn 
from a negative binomial distribution fitted to an 11-year time 
series (2006–2016) of monthly DHF case notifications from the 
intervention and control areas prior to Wolbachia deployment. 
Post-intervention time periods of 1, 2, 3 or 4 years were simulated, 
with the pre-intervention period fixed at 7 years (maximum total 
simulated time series of 11 years). Dengue case numbers were 
not modified for the untreated control area, and for the Wolbachia 
intervention area were either kept at baseline values (for the sim-
ulation at the null; i.e. relative risk (RR)=1) or reduced propor-
tionately (for simulations of intervention effects of RR=0.7, 0.6, 
0.5, 0.4, 0.3). For each of these five ‘true’ effect sizes, applied 
to each of the 1000 simulated time series, the ‘observed’ effect 
size was calculated from a negative binomial regression model 
of monthly case counts in the intervention and control areas, 
as described above. Power was estimated from the proportion 
of 1000 simulated scenarios in which a significant intervention 
effect (p<0.05) was observed (Figure 3). With seven years of 
pre-intervention data and one year post-intervention follow-
up, there was 80% power to detect a ≥30% reduction in dengue 
incidence (incidence rateratio (IRR)=0.7). There was only a 
marginal gain in power from >1 year of follow-up, if the true 
reduction in dengue incidence is greater than 30%. Power 
calculations were performed using R version 3.5.0 (R Foundation 
for Statistical Computing, Austria) with the “MASS” package26 
used for estimation of theregression models.
Regulatory and ethics approval and consent
An independent risk assessment conducted by the Indonesia 
Ministry of Research, Technology and Higher Education in 
2016 concluded that over the next 30 years, there is a negligible 
risk of harm as a result of releasing Wolbachia-infected 
Ae. aegypti27.
Approval to release Wolbachia mosquitoes was obtained from 
the provincial and city governments of Yogyakarta prior to 
releases. Ethical approval was obtained from the Universitas 
Gadjah Mada Faculty of Medicine, Public Health and Nursing 
Ethics Committee (approval number KE/FK/105/EC/2016) to 
release Wolbachia mosquitoes, for blood-feeding the mosquito 
colony on human volunteers, and to access non-identifiable 
aggregate data on monthly notified DHF and DF case numbers 
Figure 3. Power estimation. Power to detect a Wolbachia-associated reduction in dengue incidence using interrupted time series analysis 
was calculated as the proportion of significant results out of 1,000 simulations for varying post-intervention observation periods and relative 
risks.
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from the Yogyakarta DHO. Approval to conduct the household 
surveys of community acceptance was also obtained from the 
UGM Ethics Committee (approval number KE/FK/1023/EX/2015). 
Written agreement to share dengue surveillance data and 
non-identifiable individual dengue RDT results from puskesmas 
clinics was obtained from Yogyakarta DHO.
Verbal and written consent was obtained from heads of house-
holds for participating in the baseline surveys, and for hosting a 
BG trap or MRC. BG hosts were compensated 50,000 IDR for 
the cost of powering traps.
Results
Wolbachia establishment
Longitudinal entomological monitoring demonstrated rapid 
establishment of Wolbachia in the intervention areas, a continuous 
increase in Wolbachia prevalence in trapped Ae. aegypti 
throughout the first year post-release, and persistence at a very 
high prevalence ever since (Figure 4). The median Wolbachia 
prevalence was 73% (range 67–92%) one week after releases 
stopped, and 100% (96–100%) two years post-deployment. In the 
control areas, single Wolbachia-infected Ae. aegypti mosquitoes 
were detected on 11 occasions, but there has been no evidence 
of Wolbachia establishment.
Dengue incidence in intervention and control areas
In the decade prior to Wolbachia releases, dengue outbreaks 
occurred annually in both the intervention and control areas 
(Figure 4). A median of 125 DHF cases were notified each year 
in the intervention area (range 65–308), corresponding to a 
median annual incidence of 169 per 100,000 population (range 
98–477 per 100,000). In the control area, a median of 44 DHF 
cases were notified each year (range 19–159) corresponding to 
a median annual incidence of 130 per 100,000 (range 59–477 
per 100,000). Per-capita dengue incidence in the intervention 
area was on average 15% higher than the control area during the 
pre-intervention period (crude IRR 1.15, p = 0.002). Monthly 
dengue incidence in the intervention and control areas was 
highly correlated over time (Spearman’s rho = 0.75, p<0.001), 
supporting the validity of the control area as a counterfactual for 
evaluating the epidemiological impact of Wolbachia releases 
(Figure 5).
Figure 4. Wolbachia infection prevalence in local Aedes aegypti mosquito populations. Lines show the percentage of Aedes aegypti 
collected from intervention areas (closed circles; solid line) and untreated control areas (open circles; dashed line) that were Wolbachia 
infected, each week since the start of deployments until September 2019. For the intervention areas, week 0 is the week in which deployment 
commenced (between 15 August and 18 September 2016, see Table 2). For the control areas, week 0 is the week in which the first deployments 
commenced in the intervention area (15 August 2016). Shaded area indicates release period.
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Wolbachia-associated reduction in dengue incidence
During two years following the completion of Wolbachia 
deployments (April 2017–March 2019), 34 DHF cases were 
notified from the intervention area and 53 from the control 
area, corresponding to 67% lower crude incidence in the 
Wolbachia-treated area (26 vs 79 cases per 100,000 person-years; 
IRR = 0.33, p<0.001).
In an interrupted time series (ITS) analysis of monthly DHF 
case notifications January 2006 – March 2019, which adjusts for 
baseline differences between the intervention and control areas 
and seasonal and inter-annual time effects, this translates to a 
73% reduction in notified DHF incidence (95% CI 49%,86%; 
p<0.001) associated with the Wolbachia intervention.
In an exploratory analysis including six months of additional 
post-intervention data to September 2019, the DHF incidence 
in intervention vs control areas was 30 vs 115 per 100,000 
person-years (crude IRR = 0.26, p<0.001) which translates in 
the regression model to a 76% reduction in dengue incidence 
(95% CI 60%,86%; p<0.001) associated with the Wolbachia 
intervention
During the first 2.5 years post-intervention (April 2017– 
September 2019), 97 cases (DF + DHF) were notified from the 
intervention area and 137 from the control area (60 vs 163 per 
100,000 person-years; IRR = 0.37, p<0.001) corresponding to 
63% lower crude incidence in the Wolbachia-treated area, using 
a combined endpoint of DF and DHF case notifications. The lack 
of pre-release data on hospitalised DF cases precluded an ITS 
analysis with this combined endpoint.
Dengue diagnostic findings in intervention and control 
areas
Prior to Wolbachia deployments (March 2016 – March 2017), 
there was no difference between intervention and control areas in 
the proportion of tested patients with an NS1-positive RDT result 
(127/447 (28%) in intervention area vs 106/408 (26%) in 
control area; Fisher’s exact p=0.44; Figure 5). By comparison, 
in the post-intervention period (April 2017–September 2019) 
NS1 positivity was significantly lower in the intervention area 
than the control area (6/568 (1%) vs 61/429 (14%); Fisher’s exact 
p<0.001; Figure 6).
Discussion
Enabled by a successful community engagement campaign, 
release of wMel Wolbachia-carrying mosquitoes throughout 
an urban community of 65,000 people in Yogyakarta City, 
Indonesia, resulted in rapid introgression and durable establish-
ment of Wolbachia in the local Ae. aegypti population. Predefined 
analysis of public health surveillance data on dengue case 
notifications demonstrated a 73% reduction in DHF incidence 
in the intervention area during the 2 years after Wolbachia 
deployment, compared to a counterfactual untreated control 
area with a comparable historical incidence of disease. These 
epidemiological data from a dengue endemic setting are 
consistent with previous positive public health findings in 
Australia17,18.
Nazni et al. recently reported on wAlbB establishment in 
Ae. aegypti in Kuala Lumpur, Malaysia including results of 
an exploratory analysis suggestive of a modest reduction 
(40%, 95%CI 5–65%) in dengue incidence in release areas 
compared to several untreated control areas28. Nazni et al. elected 
to use the wAlbB strain on the basis of a better thermostability 
profile than wMel in the mosquito larval life stages. However we 
found no evidence that wMel establishment was compromised 
in the climatic conditions of Yogyakarta. Elsewhere Ross et al. 
reported that heatwaves have only transient effects on wMel fre-
quencies in Australia29. Evidence from pilot field studies is likely 
the best method for selecting the optimal Wolbachia strain for 
deployment in a given setting.
Figure 5. Dengue incidence in intervention and control areas, before and after the Wolbachia intervention. Monthly notified dengue case 
incidence (per 100,000 population) in the intervention (solid line) and control (dashed line) areas before and after Wolbachia deployments, 
January 2006 - September 2019. Blue shading indicates the Wolbachia infection prevalence in Ae. aegypti collected from the intervention 
area.
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By chance, the commencement of Wolbachia releases in the 
quasi-experimental study area in late 2016 coincided with the 
largest dengue epidemic on record in Yogyakarta City. Unsur-
prisingly, dengue case notifications to the District Health 
Office from across Yogyakarta City were then lower during 
2017 and 2018 than in any two-year period in the previous 
25 years, and it is notable that a highly significant Wolbachia-
associated effect was observed even during this period of record 
low dengue transmission. A resurgence in dengue incidence 
was seen throughout southeast Asia in 201930, including in 
Indonesia. Our exploratory analysis including an additional 
six months of observations after the a priori analysis time 
point of March 2019 showed a small strengthening of the inter-
vention effect and tighter confidence intervals around the point 
estimate. Evidence of field effectiveness will continue to 
accumulate throughout subsequent dengue epidemic seasons. Our 
a priori analysis plan includes re-estimation of the intervention 
effect every 12 months, until five years post-intervention.
The dengue case time series used to evaluate the effective-
ness of wMel Wolbachia included only hospitalised patients 
with a clinical diagnosis of DHF, which was historically the 
case definition for mandatory notification in Indonesia. Using 
additional notifications data available since January 2017 for 
patients hospitalised with a clinical diagnosis of dengue fever 
(DF), we saw moderate attenuation of the intervention effect com-
pared with the endpoint of DHF alone (63% vs 74% lower crude 
incidence in intervention area). Rather than a real interaction 
between the intervention effect and disease severity, we 
hypothesise that this reflects the reduced specificity of the DF 
clinical case definition compared with DHF, and the limited 
usage of confirmatory diagnostic tests; i.e. a greater proportion 
of notified DHF cases than DF cases represent true DENV infec-
tions. The hospitalised dengue patient population represents a 
more severe clinical subgroup of a much larger clinical burden, 
most of which is not counted in disease surveillance systems. 
Estimates of expansion factors from notified hospitalised cases 
Figure 6. Laboratory-confirmed dengue cases in intervention and control areas, before and after the Wolbachia intervention. 
Dengue rapid diagnostic test results for patients presenting to primary care clinics in the intervention (A) and control (B) areas. Standard 
Diagnostics Dengue Duo rapid diagnostic kits for the detection of dengue virus NS1 antigen and IgM/IgG antibody were available in primary 
care clinics throughout Yogyakarta city from March 2016, and were used at the discretion of clinic staff as part of routine clinical care. 
Monthly counts of positive and negative results for DENV NS1 antigen, as recorded by clinic staff, were aggregated for all patients 
resident in the intervention area or control area. The blue dashed line indicates the completion of Wolbachia releases in the intervention 
area in March 2017.
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to the true case burden in Indonesia range from 7–1131. The 
AWED CRCT currently underway in Yogyakarta will address 
whether the incidence of ambulatory dengue cases, who are 
usually not detected by passive dengue case surveillance 
systems, is also reduced by Wolbachia.
The results reported here are consistent with mathematical 
modelling projections. Those predictions suggested that wMel 
introgression would eliminate DENV transmission in most 
endemic settings for over a decade7,32. A recent modelling study 
estimated that Indonesia had 7.8 million (95% uncertainty 
interval 1.8–17.7 million) symptomatic dengue cases in 2015, 
which were associated with 332,865 (94,175–754,203) lost 
disability-adjusted life years16. The authors estimated that a nation-
wide wMel Wolbachia campaign could avert a large proportion 
of this burden (86.2%, 36.2–99.9%), with elimination predicted 
in low transmission settings. There are several reasons why 
elimination of DHF case notifications in the Wolbachia interven-
tion area was not observed in the present study, and was likely 
infeasible. First, the geographic scale of the intervention area 
(~5 km2) coupled with the mobility of the resident population 
means that some notified cases could have acquired their DENV 
infection at a location outside of the Wolbachia-treated area. 
Second, the specificity of DHF case reporting is likely to be 
imperfect, such that some DHF case notifications were not true 
dengue cases. Third, the intervention may not be entirely effica-
cious in blocking transmission of all DENV serotypes across 
the spectrum of transmission intensities that occurred during the 
period of observation.
Our study had limitations. The short-term, but open-label nature 
of releasing Wolbachia-infected mosquitoes means it is plau-
sible that community awareness altered healthcare seeking 
behaviour, leading to differences in DHF notifications. How-
ever, we believe this is unlikely to explain such a large and 
prolonged difference in hospitalised DHF incidence. We also 
cannot exclude a concurrent change in dengue control practices 
between the intervention and control areas, although we are 
not aware of any such alterations to standard practice. Due 
to the pragmatic nature of the study we did not determine the 
DENV serotypes circulating during the study period nor the 
incidence of other Ae. aegypti-borne diseases like Zika 
and chikungunya. The AWED CRCT currently underway in 
Yogyakarta City21 should provide further detailed evidence on 
the impact of wMel Wolbachia on the incidence of dengue, 
individual DENV serotypes and other arboviral diseases.
This study demonstrated the feasibility, acceptability and positive 
public health impact of the wMel Wolbachia introgres-
sion method in a community of 65,000 people in Yogyakarta, 
Indonesia. This represents the first field evidence from an endemic 
setting of the effectiveness of this novel strategy in reducing 
dengue incidence, and is consistent with previous results from 
northern Australia where Wolbachia deployments have resulted 
in the effective elimination of local dengue transmission. Addi-
tional epidemiological evidence from this quasi-experimental 
study, and also the AWED trial, will accumulate during 2020/21. 
Continued optimisation of Wolbachia deployments plus 
additional long-term safety and efficacy data from a range of 
ecological and transmission settings will further enhance the 
attractiveness of this approach for disease control efforts.
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